Therapeutic Advances in Infectious Disease (Aug 2023)

Hospitalization risk among patients with Mpox infection—a propensity score matched analysis

  • Andrés F. Henao-Martínez,
  • Chloe M. Orkin,
  • Boghuma K. Titanji,
  • Alfonso J. Rodriguez-Morales,
  • Jorge L. Salinas,
  • Carlos Franco-Paredes,
  • Jose Tuells,
  • Daniel B. Chastain

DOI
https://doi.org/10.1177/20499361231196683
Journal volume & issue
Vol. 10

Abstract

Read online

Background: Monkeypox (Mpox) is a reemerging, neglected viral disease. By May 2023, worldwide Mpox cases surpassed 87,000. Predictive factors for hospitalization with Mpox are lacking. Objective: We aim to compare clinical characteristics and outcomes in hospitalized and nonhospitalized patients with Mpox infection. Design: A multicenter retrospective case-control cohort of patients with Mpox infection. Methods: We performed a propensity score match analysis from a global health network (TrinetX). We compare clinical characteristics and outcomes between hospitalized and nonhospitalized patients with Mpox. Results: Of 1477 patients, 6% were hospitalized, 52% required an ED visit, and 29% received treatment at urgent care. After propensity score matching, 80 patients remained in each group. Hospitalizations were more common among Black persons (51% versus 33%, p = 0.01), people with HIV (50% versus 20%, p < 0.0001), and those with proctitis (44% versus 12.5%, p < 0.001). Conclusion: Independent predictive factors of hospitalization in our cohort for Mpox included people who are Black with a diagnosis of HIV, severe proctitis, pain requiring opioids, and elevated lactate dehydrogenase. Greater recognition of factors associated with increased risk of Mpox severity and hospitalization is paramount.